1. Home
  2. NCRA vs SYBX Comparison

NCRA vs SYBX Comparison

Compare NCRA & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$1.23

Market Cap

13.2M

ML Signal

HOLD

Logo Synlogic Inc.

SYBX

Synlogic Inc.

N/A

Current Price

$1.07

Market Cap

15.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCRA
SYBX
Founded
2002
N/A
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
15.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NCRA
SYBX
Price
$1.23
$1.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
49.7K
68.3K
Earning Date
04-01-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,106,275.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.70
$0.90
52 Week High
$2.40
$1.96

Technical Indicators

Market Signals
Indicator
NCRA
SYBX
Relative Strength Index (RSI) 56.94 26.78
Support Level $0.83 $1.01
Resistance Level $0.95 $1.20
Average True Range (ATR) 0.10 0.09
MACD 0.04 -0.03
Stochastic Oscillator 85.11 13.89

Price Performance

Historical Comparison
NCRA
SYBX

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Share on Social Networks: